Analysts initiated coverage of Kymera Therapeutics with an Outperform rating and $70 price target, citing confidence in the company’s lead experimental drug for atopic dermatitis.

Kymera Therapeutics (KYMR) stock rises as RBC Capital Markets starts coverage with an Outperform recommendation, citing potential of lead drug KT-621. Read more here.

Apollo Therapeutics’ $15 million bet on Avalo’s anti-IL-18 monoclonal antibody appears to have paid off after the candidate ...

Early onset atopic dermatitis and food allergy, among other factors, indicate greater risk for moderate to severe asthma in ...